KEY POINTS
- The Children’s Oncology Group AYA and Radiation Oncology Committees focus specifically on patients aged 15–39 years, a population spanning traditional pediatric and adult oncology practice but poorly represented in radiation-specific evidence.
- Neurocognitive effects after cranial RT can involve processing speed, attention and executive function and may emerge more than 10 years after treatment. Existing evidence is difficult to isolate from tumor, surgery and systemic therapy effects, and most quantitative dose-response models come from younger pediatric populations.
- Endocrine morbidity is substantial: approximately 40–50% of childhood and AYA cancer survivors develop at least one endocrine disorder. Growth-hormone impairment may occur from hypothalamic-pituitary doses around 20 Gy, while central hypothyroidism and ACTH deficiency have been associated with mean doses around ≥22 Gy and ≥34 Gy, respectively.
- Adolescence may represent a particular spinal-cord vulnerability. A previous COG analysis of patients aged 13–21 years receiving RT plus intrathecal chemotherapy reported up to a 30-fold higher risk of ascending myelopathy compared with younger children.
- Cardiovascular effects can emerge decades later. In one matched AYA survivor study, radiation exposure of ≥30 Gy was associated with higher cardiomyopathy/heart-failure risk (IRR 2.6, 95% CI 1.2–5.7; p=0.02).
- The report also emphasizes fertility, sexual health, financial toxicity, education, employment and social integration. More than one-third of AYAs returning to work in cited survivorship studies reported difficulty performing their jobs or required workplace accommodations.
- The central problem is that neither adult QUANTEC nor pediatric PENTEC constraints necessarily represent the 15–39-year population. The authors call for prospective AYA registries, systematic PRO collection and greater inclusion of AYAs in trials; they also note that AYAs may have poorer access to proton therapy than pediatric patients with comparable diagnoses.
CLINICAL TAKEAWAY
AYA radiation oncology should not simply borrow pediatric constraints for younger patients and adult assumptions for older ones. Treatment discussions should deliberately include fertility, endocrine and cardiovascular risk, neurocognition, psychosocial development and long-term independence while the field builds genuinely AYA-specific prospective evidence.